Comparison of SPRY2 levels in CLL cells from good- and poor-prognosis patients. To compare the expression of SPRY2, CLL cells were isolated from PB of good- and poor-prognosis patients. (A) Relative messenger RNA level of spry2 from transcriptome analyses of 7 good-prognosis and 8 poor-prognosis CLL patients (n = 15). RNA isolated from PB CLL cells was used for sequencing. The expression was normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and genomic reference DNA was used as control for transcriptome analysis. (B) Real-time polymerase chain reaction measurement of relative expression of spry2 in CLL cells from good- and poor-prognosis patients, normalized with GAPDH. (C) Levels of SPRY2 protein expression was measured in good-prognosis patients (n = 8) and poor-prognosis patients (n = 8). Displayed is a scanned western blot showing reduced protein levels of SPRY2 in poor-prognosis CLL patients. Mononuclear cells from healthy donors were used as positive control for antibody. A total of 50 μg of protein was loaded on 10% sodium dodecyl sulfate gel and β-actin was used as loading control. (D) Microarray data showing low relative expression of SPRY2 in patients with high CD38 expression. Patients with >30% of CD38-positive cells were considered CD38 high (n = 15) and patients with <30% were considered low CD38 (n = 23). GAPDH was used to normalize the value. P = .0045.